Vet­er­an amy­loid cham­pi­on helps Alzheimer's start­up grab $160M in IPO as in­vestors charge back in to a once fad­ed field

The amy­loid be­ta the­o­ry in Alzheimer’s re­search has staged a come­back with in­vestors as well as the FDA.

Thurs­day morn­ing Acu­men Phar­ma­ceu­ti­cals priced its up­sized …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER